Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

nt tools for employees; development and commencement of rollout of corporate brand positioning; and maintenance of robust risk management practices including internal controls.

The markets in which the Group conducts its business are highly competitive and highly regulated. The health care industry is experiencing:

    - pressure from governments and healthcare providers to keep prices low
      while increasing access to drugs;

    - increased R&D costs as development programs are typically larger and
      take longer to get approval from regulators;

    - challenges to existing patents from generic manufacturers;

    - low cost generic drugs entering the market on expiration of patent
      protection; and

    - higher marketing costs due to the use of direct to consumer campaigns
      in the US and competition for market share.

Shire's strategy to become the leading specialty biopharmaceutical company has been developed to address these industry-wide competitive pressures. This strategy has resulted in a series of initiatives in the following areas:

Markets

Historically, Shire's portfolio of approved products has been heavily weighted towards the North American market. With the acquisition of Transkaryotic Therapies Inc ('TKT') in 2005 and the establishment of our HGT business, Shire has substantially increased its presence in Europe and thereby diversified the risk associated with being reliant on one geographic market. Through the TKT acquisition, Shire acquired ELAPRASE (global rights) and REPLAGAL (which is presently sold only outside the US) and through the Jerini acquisition, FIRAZYR (global rights). In addition, 2008 saw the European launch of FIRAZYR and the continued roll out of MEZAVANT and FOSRENOL in Europe.

For 2008, sales outside North America represented approximately 24% of product sales (2007: 24%). Shire's late stage deve
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... of Compensatory Award Will Now Proceed -, MADISON, N.J., ... its motion for judgment as a matter of law on ... Scroggin v.,Wyeth, in the U.S. District Court, Eastern District of ... punitive damages award of,$19,360,000 rendered by the Little Rock jury ...
... USA Study to Evaluate Treatment of Coronary Artery Disease ... Patients in Real-World Setting, ... of the XIENCE V(TM) USA post-approval study, with six,hospital centers already ... Drug Administration approved the XIENCE V(TM),Everolimus Eluting Coronary Stent System. The ...
... 10 most promising drugs ... TSX Exchange Symbol: ... the "Company") (TSX:RVX) novel lead ApoA-I drug,candidate, RVX-208 has been ... (CVD) drugs available for strategic partnering by an,independent committee assembled ...
Cached Biology Technology:Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 2Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 3Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 2Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 3Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 4Industry Leaders Select Resverlogix's RVX-208 2Industry Leaders Select Resverlogix's RVX-208 3
(Date:12/3/2014)... , Dec. 2, 2014   Marvin ... deployed, innovative test solutions for military, aerospace, and ... version of its successful TS-900 PXI semiconductor ... and features of high-end systems to customers at ... value compared to traditional ATE. ...
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... bird flu virus H5N1 emerged in late 2005 and replaced ... southern China, despite an ongoing program to vaccinate poultry, according ... with scientists at St. Jude Children's Research Hospital. , The ... the increased occurrence of H5N1 poultry infections since October 2005, ...
... first large-scale analysis of proteins in the brains of ... and mechanisms that may one day lead to new ... in the current issue of Molecular Psychiatry, released on-line ... and point to profound changes in brain function related ...
... immune response to the 1918 influenza virus provides new ... in an article appearing online today in the journal ... 1918 virus triggers a hyperactive immune response that may ... their results suggest that it is the combination of ...
Cached Biology News:Control measures fail to stop spread of new H5N1 virus 2High-tech research shows cocaine changes proteins and brain function 2Mouse study reveals new clues about virulence of 1918 influenza virus 2Mouse study reveals new clues about virulence of 1918 influenza virus 3
MMP-1/8 (H-300)...
Gastric Carcinoma Marker [BY-1 (3H11)]...
Mouse VEGF R1/Flt-1 Phycoerythrin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Mouse VEGF R1/Flt-1 Allophycocyanin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Biology Products: